Widespread haploid-biased gene expression enables sperm-level natural selection.

Autor: Bhutani K; Ohana Biosciences, Cambridge, MA, USA., Stansifer K; Ohana Biosciences, Cambridge, MA, USA., Ticau S; Ohana Biosciences, Cambridge, MA, USA., Bojic L; Ohana Biosciences, Cambridge, MA, USA., Villani AC; Center for Immunology and Inflammatory Diseases, Center for Cancer Research, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Slisz J; Ohana Biosciences, Cambridge, MA, USA., Cremers CM; Ohana Biosciences, Cambridge, MA, USA., Roy C; Ohana Biosciences, Cambridge, MA, USA., Donovan J; Ohana Biosciences, Cambridge, MA, USA., Fiske B; Ohana Biosciences, Cambridge, MA, USA., Friedman RC; Ohana Biosciences, Cambridge, MA, USA. robin.friedman@ohanabio.com.

Publikováno v: Science (New York, N.Y.) [Science] 2021 Mar 05; Vol. 371 (6533). Date of Electronic Publication: 2021 Jan 14.

Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation.

Autor: Yuan Z; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Zhang M; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Chang L; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Chen X; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Ruan S; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Shi S; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Zhang Y; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China., Zhu L; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China. zhulfl@ecust.edu.cn., Li H; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China. hlli@ecust.edu.cn.; Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai, 200062, China. hlli@ecust.edu.cn.; Lingang Laboratory, Shanghai, 200031, China. hlli@ecust.edu.cn., Li S; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai, China. slli403@163.com.; Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai, 200062, China. slli403@163.com.

Publikováno v: Journal of molecular modeling [J Mol Model] 2024 Apr 13; Vol. 30 (5), pp. 131. Date of Electronic Publication: 2024 Apr 13.

Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.

Autor: Kim, Jinseong^1,2 (AUTHOR), Shim, Man Kyu³ (AUTHOR), Moon, Yujeong^3,4 (AUTHOR), Kim, Jeongrae^1,2 (AUTHOR), Cho, Hanhee¹ (AUTHOR), Yun, Wan Su^1,2 (AUTHOR), Shim, Nayeon¹ (AUTHOR), Seong, Joon-Kyung⁴ (AUTHOR), Lee, Yonghyun¹ (AUTHOR), Lim, Dong-Kwon² (AUTHOR), Kim, Kwangmeyung¹ (AUTHOR) kimkm@ewha.ac.kr

Publikováno v: Journal of Nanobiotechnology. 3/13/2024, Vol. 22 Issue 1, p1-19. 19p.

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Autor: Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD

Publikováno v: Nature [Nature] 2016 Jul 07; Vol. 535 (7610), pp. 148-52. Date of Electronic Publication: 2016 Jun 29.

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.

Autor: Masci, Domiziana¹ (AUTHOR) domiziana.masci@unicatt.it, Naro, Chiara^2,3 (AUTHOR) chiara.naro@unicatt.it, Puxeddu, Michela⁴ (AUTHOR) michela.puxeddu@uniroma1.it, Urbani, Andrea¹ (AUTHOR) andrea.urbani@unicatt.it, Sette, Claudio^2,3 (AUTHOR) claudio.sette@unicatt.it, La Regina, Giuseppe⁴ (AUTHOR) giuseppe.laregina@uniroma1.it, Silvestri, Romano⁴ (AUTHOR) romano.silvestri@uniroma1.it

Publikováno v: Molecules. Nov2023, Vol. 28 Issue 22, p7513. 48p.